Wedmont Private Capital Purchases 1,042 Shares of Eli Lilly and Company $LLY

Wedmont Private Capital increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 7.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 14,519 shares of the company’s stock after purchasing an additional 1,042 shares during the quarter. Wedmont Private Capital’s holdings in Eli Lilly and Company were worth $16,088,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Sumitomo Mitsui Financial Group Inc. purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $27,000. Vermillion & White Wealth Management Group LLC grew its holdings in shares of Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after acquiring an additional 16 shares in the last quarter. Evolution Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $29,000. Steph & Co. increased its position in shares of Eli Lilly and Company by 290.0% during the third quarter. Steph & Co. now owns 39 shares of the company’s stock valued at $30,000 after acquiring an additional 29 shares during the last quarter. Finally, Bare Financial Services Inc lifted its holdings in Eli Lilly and Company by 263.6% during the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock worth $31,000 after acquiring an additional 29 shares during the period. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on LLY. Loop Capital set a $1,200.00 price objective on Eli Lilly and Company in a research note on Tuesday, February 10th. Scotiabank reiterated an “outperform” rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Zacks Research downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. BMO Capital Markets restated an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $1,221.44.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $910.59 on Tuesday. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. The stock has a fifty day simple moving average of $1,019.76 and a two-hundred day simple moving average of $960.48. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The firm has a market cap of $860.34 billion, a price-to-earnings ratio of 39.68, a price-to-earnings-growth ratio of 1.05 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period in the previous year, the company posted $5.32 earnings per share. The business’s revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly expanded access for its weight‑loss drug Zepbound by launching a self‑pay option (starting at $299/month for the low dose) through LillyDirect and major pharmacies — a move that should broaden the addressable market and help revenue growth if uptake scales. Eli Lilly and Company (LLY) Expands Zepbound Access as Pricing Reforms Boost Long-Term Growth Outlook
• Positive Sentiment: Analysts continue to point to upside after Lilly’s strong February quarter (revenue and EPS beats and raised FY guidance); several pieces highlight upgraded price targets and room for further appreciation based on product momentum. Here’s How Much Upside Eli Lilly Stock Has, According to Analysts
• Neutral Sentiment: Lilly’s leadership joined other U.S. CEOs at the China Development Forum and signaled renewed investment in China; management interest supports long‑term expansion but geopolitical uncertainty keeps execution risk elevated. U.S. executives, from Apple to Eli Lilly, revamp their push into the world’s second-largest economy at the China Development Forum
• Neutral Sentiment: Local planning discussions about a proposed Eli Lilly plant in Lehigh Valley signal capacity expansion plans that could support manufacturing scale — watch for permitting/timeline news that would affect capital expenditure and supply. Lehigh Valley planners to discuss traffic, other potential issues with proposed Eli Lilly plant
• Neutral Sentiment: Market commentary flags an upcoming April 10 event described as a “make‑or‑break” test versus rival Novo Nordisk — this creates short‑term binary risk around competitive positioning in obesity/GLP‑1 markets. Eli Lilly Stock (LLY) Faces This Make-or-Break Test on April 10
• Negative Sentiment: Benzinga and other outlets note the U.S. Supreme Court revived Actos litigation exposure — renewed legal risk could create headline volatility and potential liabilities. What’s Going On With Eli Lilly On Monday?
• Neutral Sentiment: “Should you buy before April 10?” pieces are framing short‑term timing decisions for investors; they reiterate the same balance of strong fundamentals versus near‑term competitive and legal catalysts. Should You Buy Eli Lilly Stock Before April 10?

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.